Galapagos NV (NASDAQ:GLPG) had its price target dropped by stock analysts at Nomura from $108.00 to $121.00 in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Nomura’s target price indicates a potential upside of 56.43% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Instinet started coverage on Galapagos NV in a research report on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price objective for the company. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research report on Tuesday, March 7th. Cowen and Company reaffirmed a “buy” rating on shares of Galapagos NV in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Tuesday. Finally, TheStreet raised Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Galapagos NV has a consensus rating of “Buy” and an average target price of $90.50.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Shares of Galapagos NV (GLPG) traded up 2.31% during trading on Thursday, hitting $79.14. The stock had a trading volume of 103,344 shares. The company has a market cap of $3.66 billion, a PE ratio of 768.35 and a beta of 1.77. Galapagos NV has a 12-month low of $49.43 and a 12-month high of $94.88. The stock’s 50 day moving average is $83.52 and its 200-day moving average is $75.77.

ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/22/galapagos-nv-glpg-given-new-121-00-price-target-at-nomura.html.

A number of hedge funds and other institutional investors have recently modified their holdings of GLPG. Tower Research Capital LLC TRC purchased a new position in shares of Galapagos NV during the first quarter worth $161,000. Bank of Montreal Can boosted its position in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares in the last quarter. Cim Investment Mangement Inc. bought a new position in shares of Galapagos NV during the first quarter worth approximately $203,000. Karp Capital Management Corp bought a new position in shares of Galapagos NV during the first quarter worth approximately $206,000. Finally, Airain ltd bought a new position in shares of Galapagos NV during the first quarter worth approximately $237,000. Hedge funds and other institutional investors own 19.94% of the company’s stock.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.